Treatment of Relapsed DLBCL

Approximately one third of patients with DLBCL will relapse and require second line therapy. Currently patients are stratified by those who are candidates for high dose chemotherapy with curative intent, or patients who are not candidates for high dose chemotherapy and area managed palliatively. Patients who are sufficiently young and fit for intensive therapy undergo second line treatment with a non-cross-resistant chemotherapy regimen such as R-ICE, R-DHAP, or R-GDP, each of which has similar efficacy in this setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research